300 million child-friendly antimalarial treatments supplied without profit by Novartis
- Details
- Category: Novartis
Novartis announced today that it has reached a delivery milestone of 300 million pediatric antimalarial treatments supplied without profit since 2009, helping to reduce the disease burden for children in more than 30 malaria-endemic countries.
AstraZeneca and Voluntis to test companion mobile app in ovarian cancer studies with the US National Cancer Institute
- Details
- Category: AstraZeneca
AstraZeneca announced plans to test a digital support service for women undergoing treatment for recurrent platinum-sensitive high-grade ovarian cancer in clinical trials of cediranib plus olaparib. Voluntis has developed the service in close clinical collaboration with AstraZeneca and the US National Cancer Institute (NCI).
Daratumumab combined with standard treatment for multiple myeloma produced deep and durable responses in relapsed or refractory patients
- Details
- Category: Johnson & Johnson
Janssen-Cilag International NV announced new data from the ongoing Phase 1/2 GEN503 investigational study showing the human CD38-directed monoclonal antibody daratumumab, in combination with lenalidomide and dexamethasone, yielded an overall response rate (ORR) of 81 percent in relapsed or refractory multiple myeloma patients who had received a median of two prior therapies.
GSK receives European marketing authorisation for Nucala® (mepolizumab) in 31 countries
- Details
- Category: GlaxoSmithKline
GlaxoSmithKline (LSE/NYSE: GSK) today announced that the European Commission has granted marketing authorisation for Nucala® (mepolizumab) as an add-on treatment for severe refractory eosinophilic asthma in adult patients. As a result Nucala is now approved for use in the 31 European countries covered by the European Medicines Agency (EMA).
Roche and Upsher-Smith announce license agreement to develop novel VAP-1 inhibitor
- Details
- Category: Roche
Roche (SIX: RO, ROG: OTCQX: RHHBY) and Upsher-Smith Laboratories, Inc. (Upsher-Smith), through its wholly-owned UK subsidiary Proximagen Ltd., announced a worldwide agreement for the further development of a novel, oral small molecule inhibitor of Vascular Adhesion Protein 1 (VAP-1), a cell-adhesion molecule that may be effective in the treatment of inflammatory diseases.
Bristol-Myers Squibb Foundation marks World AIDS Day with grants totaling more than $3.5M
- Details
- Category: Bristol-Myers Squibb
To mark World AIDS Day, the Bristol-Myers Squibb Foundation today announced 16 grants totaling $3.5 million for programs in Africa that strengthen HIV services for adolescents and the elderly, raise awareness and access to health care for women co-diagnosed with HIV and breast or cervical cancer, and build community capacity and integrate treatment for HIV/tuberculosis (TB) co-infection.
Praxbind® (idarucizumab) approved in European Union for the specific reversal of Pradaxa® (dabigatran etexilate)
- Details
- Category: Boehringer Ingelheim
The European Commission has approved Praxbind® (idarucizumab), a treatment to rapidly and specifically reverse the anticoagulant effects of Pradaxa® (dabigatran etexilate) in cases of emergency surgery /urgent procedures or in situations of life-threatening or uncontrolled bleeding.
More Pharma News ...
- Roche receives EU approval of Cotellic for use in combination with Zelboraf in advanced melanoma
- AstraZeneca enters into agreement with Perrigo for rights to Entocort® in the US
- Bayer's new five-year-contraceptive submitted for EU and US marketing authorization
- Merck and Pfizer receive FDA Breakthrough Therapy designation for avelumab in metastatic Merkel cell carcinoma
- Roche to restructure its manufacturing network for small molecules
- Global partners announce donation of 500 millionth dose of azithromycin
- International study prompts rethink on the rise of diabetes in cities